Novavax Inc

Financials

Overview Отчетность Statistics Dividends

Cash from operating activities 42.54 M322.95 M415.9 M714 M87.3 M244.63 M 244.63 M Cash from investing activities 377.78 M100.15 M92.98 M58.81 M204.04 M78.27 M 78.27 M Cash from financing activities 984.76 M461.71 M324.99 M4.47 M260.58 M27.74 M 27.74 M Free cash flow -12.08 M265.46 M322.92 M655.19 M72.66 M238.25 M 238.25 M

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

NVAX

Financials

Novavax Inc

Новости

Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX)

What's Going On With Novavax Stock On Friday? - Novavax (NASDAQ:NVAX)

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates

H.C. Wainwright повысил целевую цену акций Novavax

Company News for Feb 27, 2026

Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript

Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates

Novavax за IV квартал 2025: прибыль превзошла ожидания

Novavax Q4 2025 slides: earnings beat fuels partnership transformation

Акции Novavax достигли 52-недельного максимума $10,65

Novavax stock hits 52-week high at 10.65 USD

COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb - Novavax (NASDAQ:NVAX)